ArticleProceedings of the National Academy of Sciences of the United States of America2010
Bone marrow transplantation restores epidermal basement membrane protein expression and rescues epidermolysis bullosa model mice.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 63 citations in OpenAlex.
- Macrophage- and pluripotent-like reparative Muse cells are unique endogenous stem cells distinct from other somatic stem cells.Frontiers in bioengineering and biotechnology · 2025Review
- Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa.International journal of molecular sciences · 2024Review
- Donor Muse Cell Treatment Without HLA-Matching Tests and Immunosuppressant Treatment.Stem cells translational medicine · 2024Review
- Genes and compounds that increase type VII collagen expression as potential treatments for dystrophic epidermolysis bullosa.Experimental dermatology · 2022Article
- Article
- Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- An Update on the Potential of Mesenchymal Stem Cell Therapy for Cutaneous Diseases.Stem cells international · 2021Review
- Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.Expert opinion on biological therapy · 2020Review
- Role of B7H3/IL-33 Signaling in Pulmonary Fibrosis-induced Profibrogenic Alterations in Bone Marrow.American journal of respiratory and critical care medicine · 2019Article
- Current and Future Perspectives of Stem Cell Therapy in Dermatology.Annals of dermatology · 2017Review
- Next generation human skin constructs as advanced tools for drug development.Experimental biology and medicine (Maywood, N.J.) · 2017Review
- Revertant mosaicism in genodermatoses.Cellular and molecular life sciences : CMLS · 2017Review
- CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa.NPJ Regenerative medicine · 2016Article
- From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Review
- Placenta-based therapies for the treatment of epidermolysis bullosa.Cytotherapy · 2015Review
- Induced pluripotent stem cells in dermatology: potentials, advances, and limitations.Cold Spring Harbor perspectives in medicine · 2014Review
- Pharmacological mobilization of endogenous stem cells significantly promotes skin regeneration after full-thickness excision: the synergistic activity of AMD3100 and tacrolimus.The Journal of investigative dermatology · 2014Article
- Augmentation of cutaneous wound healing by pharmacologic mobilization of endogenous bone marrow stem cells.The Journal of investigative dermatology · 2014Article
- Cell therapy in dermatology.Cold Spring Harbor perspectives in medicine · 2014Review
- Promise of human induced pluripotent stem cells in skin regeneration and investigation.The Journal of investigative dermatology · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attempts to treat congenital protein deficiencies using bone marrow-derived cells have been reported. These efforts have been based on the concepts of stem cell plasticity. However, it is considered more difficult to restore structural proteins than to restore secretory enzymes. This study aims to clarify whether bone marrow transplantation (BMT) treatment can rescue epidermolysis bullosa (EB) caused by defects in keratinocyte structural proteins. BMT treatment of adult collagen XVII (Col17) knockout mice induced donor-derived keratinocytes and Col17 expression associated with the recovery of hemidesmosomal structure and better skin manifestations, as well improving the survival rate. Both hematopoietic and mesenchymal stem cells have the potential to produce Col17 in the BMT treatment model. Furthermore, human cord blood CD34(+) cells also differentiated into keratinocytes and expressed human skin component proteins in transplanted immunocompromised (NOD/SCID/gamma(c)(null)) mice. The current conventional BMT techniques have significant potential as a systemic therapeutic approach for the treatment of human EB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.